ASH 2016 Abstract 234. Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 6. Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 1151. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed…
jwood@krftwrk.caJanuary 10, 2017
ASH 2016 Abstract 1105. Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination…
jwood@krftwrk.caJanuary 10, 2017
